文献速递心律失常冠心病

房颤患者PCI术后双联与三联抗栓治疗的安全性和疗效:随机临床试验的系统综述与荟萃分析

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.
PubMed 文献 · Eur Heart J · 2018-01-01

该系统综述与荟萃分析纳入4项随机试验共5317例房颤合并PCI患者,比较双联抗栓(DAT)与三联抗栓(TAT)的安全性和疗效。结果显示DAT组TIMI大或小出血减少47%(4.3% vs 9.0%;HR 0.53,95%CrI 0.36-0.85),而主要不良心血管事件(MACE)无差异(10.4% vs 10.0%;HR 0.85,95%CrI 0.48-1.29)。结论支持DAT可能优于TAT。

要点

  • 房颤合并PCI患者中,DAT较TAT减少TIMI大或小出血47%。
  • DAT与TAT在MACE、全因死亡、心源性死亡、心肌梗死、支架血栓和卒中方面无差异。
  • 结果支持DAT可作为许多房颤PCI术后患者优于TAT的选择。

核心结论

  • 与TAT相比,DAT使TIMI大或小出血减少47%,且MACE结局相当。
  • 研究结果支持DAT在房颤PCI术后患者中可能优于TAT。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、EBSCO、Cochrane系统综述数据库、Web of Science及相关会议摘要。
  • 纳入4项比较房颤PCI术后患者DAT与TAT的3期随机试验,共5317例患者,其中3039例(57%)接受DAT。

主要发现

  • DAT组TIMI大或小出血发生率为4.3%,TAT组为9.0%(HR 0.53,95%CrI 0.36-0.85,I2=42.9%)。
  • 试验定义的MACE在DAT组为10.4%,TAT组为10.0%(HR 0.85,95%CrI 0.48-1.29,I2=58.4%)。
  • 两组在全因死亡、心源性死亡、心肌梗死、支架血栓或卒中方面无差异。

临床怎么用

  • 对于房颤合并PCI术后的患者,可考虑优先选择DAT而非TAT以降低出血风险。
  • DAT与TAT在缺血事件方面未见差异,决策时需结合患者个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Of patients with atrial fibrillation (AF), approximately 10% undergo percutaneous coronary intervention (PCI). We studied the safety and efficacy of dual vs. triple antithrombotic therapy (DAT vs. TAT) in this population. METHODS AND RESULTS: A systematic review and meta-analysis was conducted using PubMed, Embase, EBSCO, Cochrane database of systematic reviews, Web of Science, and relevant meeting abstracts for Phase 3, randomized trials that compared DAT vs. TAT in patients with AF following PCI. Four trials including 5317 patients were included, of whom 3039 (57%) received DAT. Compared with the TAT arm, Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding showed a reduction by 47% in the DAT arm [4.3% vs. 9.0%; hazard ratio (HR) 0.53, 95% credible interval (CrI) 0.36-0.85, I2 = 42.9%]. In addition, there was no difference in the trial-defined major adverse cardiac events (MACE) (10.4% vs. 10.0%, HR 0.85, 95% CrI 0.48-1.29, I2 = 58.4%), or in individual outcomes of all-cause mortality, cardiac death, myocardial infarction, stent thrombosis, or stroke between the two arms. CONCLUSION: Compared with TAT, DAT shows a reduction in TIMI major or minor bleeding by 47% with comparable outcomes of MACE. Our findings support the concept that DAT may be a better option than TAT in many patients with AF following PCI.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Golwala HB, Cannon CP, Steg PG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018. PMID: 29668889. doi:10.1093/eurheartj/ehy162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。